Hung-Ming Lam

Abstract BPTF, the scaffolding subunit of the nucleosome remodeling factor (NURF) complex, has been implicated in the progression of several malignancies, but its role in prostate cancer (PCa) remains unclear. Here, we demonstrate that BPTF is upregulated in castration-resistant prostate cancer (CRPC) and promotes disease progression. RNA-seq revealed that BPTF primarily enhances the expression of androgen receptor (AR) target genes.

Abstract Bladder cancer is a prevalent but currently understudied cancer type and patient outcomes are poor when it progresses to the muscle-invasive stage. Current research in bladder cancer focuses on the genetic and epigenetic alterations occurring within the urothelial cell compartment; however, the stromal compartment receives less attention.

Background Prostate cancer is currently the second leading cause of cancer deaths in men with more than 33,000 deaths in the United States from prostate cancer expected in 2020 (1). The backbone of therapy for incurable prostate cancer remains androgen deprivation therapy (ADT) with the degree of initial response to ADT strongly correlating with survival.